HSBC Holdings
CDTX

HSBC Holdings’s Cidara Therapeutics CDTX Stock Holding History

HSBC Holdings’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-850
Closed -$11K – 3061
2022
Q3 		$11K Sell
850
-913
-52% -$12.6K ﹤0.01% 2885
2022
Q2 		$17K Sell
1,763
-244
-12% -$3.01K ﹤0.01% 3198
2022
Q1 		$33K Hold
2,007
– – ﹤0.01% 3218
2021
Q4 		$51K Hold
2,007
– – ﹤0.01% 3198
2021
Q3 		$90K Hold
2,007
– – ﹤0.01% 2893
2021
Q2 		$81K Buy
2,007
+622
+45% +$26.3K ﹤0.01% 2867
2021
Q1 		$74K Buy
+1,385
New +$68.4K ﹤0.01% 2649

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's CDTX Position: Q4 2022 in Review

HSBC Holdings sold out of Cidara Therapeutics (CDTX) in Q4 2022, closing a stake of 850 shares — an estimated $11K sold.

HSBC Holdings first reported a position in CDTX in Q1 2021 and held it in 7 quarters. The position peaked at $90K in Q3 2021. 42 funds tracked by Wall St. Rank hold CDTX as of Q4 2022.

  • HSBC Holdings reported no remaining Cidara Therapeutics position as of Q4 2022 after selling out during the quarter.
  • HSBC Holdings sold 850 Cidara Therapeutics shares in Q4 2022, an estimated $11K.
  • HSBC Holdings first reported a position in Cidara Therapeutics in Q1 2021 and held it in 7 quarters.
  • HSBC Holdings's Cidara Therapeutics position peaked at $90K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2022.

Based on HSBC Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.